Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)

Next Previous
Search
Trial Profile

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emestedastat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms XanADu
  • Sponsors Actinogen Medical

    • Most Recent Events

    • 26 Jun 2024 Results presented in an Actinogen Medical Media Release.
    • 26 Jun 2024 According to an Actinogen Medical media release, results from this study were presented in the Journal of Alzheimer's Disease.
    • 20 Jul 2023 Results assessing the effects of Xanamem on cognition from XanaHES (n= 42, 20 mg) and XanaMIA (n=105, 5 & 10 mg) and XanADu-X biomarker extension study (n=72, 10 mg), presented at the Alzheimer's Association International Conference 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top